75167-86-1

Basic information

• Product Name: 2-(benzyloxy)-1-Methoxy-4-nitrobenzene
• Synonyms: 2-(benzyloxy)-1-Methoxy-4-nitrobenzene;Benzene, 1-Methoxy-4-nitro-2-(phenylMethoxy)-;Benzene,1-methoxy-4-nitro-2-(phenylmethoxy)-（WS205035）
• CAS NO: 75167-86-1
• Molecular Formula: C₁₄H₁₃NO₄
• Molecular Weight: 259.25732
• Mol File: 75167-86-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(benzyloxy)-1-Methoxy-4-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(benzyloxy)-1-Methoxy-4-nitrobenzene(75167-86-1)
• EPA Substance Registry System: 2-(benzyloxy)-1-Methoxy-4-nitrobenzene(75167-86-1)

Safety Data

• Hazardous Substances Data: 75167-86-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(benzyloxy)-1-Methoxy-4-nitrobenzene is used as a synthetic intermediate for the development of various pharmaceutical drugs. Its presence of electron-withdrawing nitro and protective benzyloxy groups makes it a valuable building block in the synthesis of complex organic molecules.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(benzyloxy)-1-Methoxy-4-nitrobenzene serves as an intermediate in the production of pesticides. Its chemical properties allow for the creation of compounds that can effectively control pests and protect crops.
Used in Organic Synthesis:
2-(benzyloxy)-1-Methoxy-4-nitrobenzene is utilized as a reagent in organic synthesis reactions. Its nitro group can participate in various chemical transformations, making it a versatile component in the synthesis of a wide range of organic compounds.
Safety Considerations:
It is crucial to handle 2-(benzyloxy)-1-Methoxy-4-nitrobenzene with care due to its potential hazards. Proper storage and usage protocols must be followed to ensure the safety of individuals and the environment.

Upstream product

• 636-93-1 5-nitroguaiacol 
• 100-44-7 benzyl chloride 
• 835-79-0 1-(benzyloxy)-2-methoxybenzene 
• 7697-37-2 nitric acid 
• 64-19-7 acetic acid 
• 100-39-0 benzyl bromide 
• 67233-85-6 sodium 5-nitroguaiacolate 
• 861800-46-6 carbonic acid bis-(5-nitro-2-methoxy-phenyl ester) 
• 74-88-4 methyl iodide 

Downstream Products

• 849217-47-6 3-fluoro-4-((6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinolin-4-yl)oxy)aniline 
• 1394166-11-0 3-fluoro-4-((6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-yl)oxy)aniline 
• 479690-10-3 3-Fluoro-4-{[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy}-aniline 
• 347161-74-4 4-[(6,7-dimethoxyquinolin-4-yl)oxy]-3-fluoroaniline 

Relevant articles and documents

Discovery of AL-GDa62 as a Potential Synthetic Lethal Lead for the Treatment of Gastric Cancer

Diffuse gastric cancer and lobular breast cancer are aggressive malignancies that are frequently associated with inactivating mutations in the tumor suppressor gene CDH1. Synthetic lethal (SL) vulnerabilities arising from CDH1 dysfunction represent attrac

Synthesis and evaluation of azalamellarin N and its A-ring-modified analogues as non-covalent inhibitors of the EGFR T790M/L858R mutant

Azalamellarin N, a synthetic lactam congener of the marine natural product lamellarin N, and its A-ring-modified analogues were synthesized and evaluated as potent and non-covalent inhibitors of the drug-resistant epidermal growth factor receptor T790M/L8

Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate

A series of 1,6-naphthyridinone-based MET kinase inhibitors bearing quinoline moiety in block A were designed and synthesized based on the structures of Cabozantinib and our reported compound IV. Extensive SAR and DMPK studies led to the identification of 20j, a potent and orally bioavailable MET kinase inhibitor with favorable kinase selectivity. More importantly, 20j exhibited statistically significant tumor growth inhibition (Tumor growth inhibition/TGI of 131%, 4/6 partial regression/PR) in the U-87 MG xeograft model, which is superior to that of Cabozantinib (TGI of 97%, 2/6 PR), and significantly better than that of compound IV (TGI of 15%, 0/6 PR) at the same dose (12.5 mg/kg). Combined with favorable in vitro potency, kinase selectivity, pharmacokinetic profile and in vivo efficacy, the promising antitumor drug candidate 20j has subsequently advanced into preclinical research.

Naphthyridine compound and pharmaceutical composition as well as applications thereof

The invention relates to the field of biological medicines and discloses a naphthyridine compound and a pharmaceutical composition as well as applications thereof. The naphthyridine compound has a structure shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, hydrate, solvate, metabolite, a pharmaceutically acceptable salt or a prodrug. The naphthyridine compound disclosed by the invention has an anti-tumor effect which is obviously superior to the anti-tumor effect of the prior art. And moreover, the naphthyridine compound disclosed by the invention can treat diseases mediated by protein kinase.

Preparation method of 7-benzyloxy-6-methoxy-4-hydroxyquinoline

The invention discloses a preparation method of 7-benzyloxy-6-methoxy-4-hydroxyquinoline. The method comprises the following steps: under the action of anhydrous p-methylbenzenesulfonic acid, carrying out condensation reaction on 3-benzyloxy-4-methoxyanil

Aryloxy quinoline derivatives and their use in therapy

Disclosed herein are aryloxy quinolines derivatives,and the said compounds are compounds of formula (I) or pharmaceutically acceptable salts thereof or solvates, wherein R1, R2, R3, R4, m, n, X, Z, Ar are defined detailedly in the description. Furthermore, medicaments comprising said compounds or salts as active components and the use for treating conditions and disorders relating to protein-tyrosine kinase receptors, especially c-Met, VEGFR are also described.

Synthesis and anticancer activity of 4-aza-daurinol derivatives

Daurinol, a natural aryl naphthalene lactone, has been reported to have antiproliferative activity against various cell lines, and has also been shown to be efficacious in an in vivo xenograft mouse model. In this study, we tried to discover a new scaffold that enables both rapid structure-activity relationship study of daurinol and scalable synthesis of active compounds. 4-Aza-daurinol, a bioisosterism-based scaffold of daurinol, was designed and 17 analogues were synthesized and evaluated against five representative cancer cell lines. Among them, the 2,3-dihydrobenzo[b][1,4]dioxinyl derivative was found to be the most potent and showed similar activity and tendency as daurinol.

Identification of 3-amido-4-anilinoquinolines as potent and selective inhibitors of CSF-1R kinase

3-Amido-4-anilinoquinolines are potent and highly selective inhibitors of CSF-1R. Their synthesis and SAR is reported, along with initial efforts to optimize the physical properties and PK through modifications at the quinoline 6- and 7-positions.

COMPOUNDS AND PROCESSES FOR PREPARING SUBSTITUTED AMINOMETHYL-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-E]INDOL-8-ONES

Processes and intermediates arc provided for the preparation of substituted aminomethyl 2,3,8,9-tctrahydiO-7H-1.4-dioxino[2.3-e]indo]-8-ones of the Formula (A) wherein the variables n, R and R3 are as described herein. Such compounds are useful, for example, as dopamine receptor agonists.

QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY

Compounds of formula (IA) or (IB), are inhibitors of aurora kinase activity: Formula (IA), (IB) wherein -L1Y1-[CH2]z- is a linker radical wherein Y1, L1 and z are as defined in the claims; R6 is C1-C4alkoxy, hydrogen or halo; W represents a bond, -CH2-, -O-, -S-, -S(=O)2-, or -NR5- where R5 is hydrogen or C1-C4 alkyl; Q is =N-, =CH- or =C(X1)- wherein X1 is cyano, cyclopropyl or halo; linker radicals L2 are as defined in the claims; R is a radical of formula (X) or (Y): wherein R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R4 is hydrogen; or optionally substituted C1-C6 alkyl, C3-C7 cycloalkyl, aryl, aryl(C1-C6 alkyl)-, heteroaryl, heteroaryl(C1-C6 alkyl)-, -(C=O)R3, -(C=O)OR3, or -(C=O)NR3 wherein R3 is hydrogen or optionally substituted (C1-C6)alkyl, C3-C7 cycloalkyl, aryl, aryl(C1-C6 alkyl)-, heteroaryl, or heteroaryl(C1-C6 alkyl)-; R41 is hydrogen or optionally substituted C1-C6 alkyl; and D is a monocyclic heterocyclic ring of 5 or 6 ring atoms.